Intelligence · Clinical Development
Pipeline search results
Programs matching “Astra” across our ClinicalTrials.gov index — phase, modality, sponsor, and trial IDs.
Quick answer
Showing 467 pipeline programs matching "Astra" from NovaPharmaNews Clinical Development Intelligence — phase, modality, sponsor, and ClinicalTrials.gov trial IDs.
Refine search
Search results
-
D702AC00001
AstraZeneca AB
HER2-positive locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma.
1 trial -
D702BC00001
AstraZeneca AB
Metastatic Squamous Non-small Cell Lung Cancer Whose Tumors Express PD-L1
1 trial -
D702FC00001
AstraZeneca AB
Metastatic Non-squamous Non-small Cell Lung Cancer Whose Tumors Express PD-L1
1 trial -
D702GC00001
AstraZeneca AB
Lung Cancer
1 trial -
D702NC00001
AstraZeneca AB
Biliary Tract Cancer
1 trial -
D7310C00001
AstraZeneca AB
Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Previously Treated With an Immune Checkpoint Inhibitor
1 trial -
D7402C00001
AstraZeneca AB
Large B-cell Lymphoma
1 trial -
D7632C00001
AstraZeneca AB
Locally-advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) with high PD-L1 expression (TC ≥ 50%) and without actionable genomic alterations.
1 trial -
D781PC00001
AstraZeneca AB
Advanced HER2-expressing Biliary Tract Cancer
1 trial -
D7984C00002
AstraZeneca AB
Locally advanced cervical cancer
1 trial -
D7988C00001
AstraZeneca AB
Unresectable Pleural Mesothelioma
1 trial -
D798AC00001
AstraZeneca AB
Metastatic Non-Small Cell Lung Cancer (mNSCLC)
1 trial -
D8220C00027
AstraZeneca AB
Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
1 trial -
D8311C00001
AstraZeneca AB
Relapsed or Refractory Multiple Myeloma
1 trial -
D8532C00001
AstraZeneca AB
Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer
1 trial -
D8534C00001
AstraZeneca AB
Estrogen Receptor-Positive, HER-2 negative Advanced Breast Cancer
1 trial -
D8535C00001
AstraZeneca AB
ER+/HER2- Early Breast Cancer
1 trial -
D8610C00001
AstraZeneca AB
Respiratory Syncytial Virus and Human Metapneumovirus
1 trial -
D8991C00001
AstraZeneca AB
Advanced Platinum-resistant Epithelial Ovarian Cancer
1 trial -
D9075C00001
AstraZeneca AB
The target population of interest in this study is participants with locally advanced (Stage III), unresectable NSCLC, whose tumours express PD L1 TC ≥ 1% as assessed by a central reference laboratory using the VENTANA PD-L1 (SP263) IHC assay, and who did not progress after definitive platinum based cCRT.
1 trial -
D9078C00001
AstraZeneca AB
Patients With Locally Advanced (Stage III), Unresectable Non-small Cell Lung Cancer (NSCLC)
1 trial -
D9103C00001
AstraZeneca AB
Main cohort: Patients with unresected Stage I/II, lymph-node negative Non-small Cell Lung Cancer Osimertinib cohort: Open-label, Single arm for patients with unresected stage I/II, lymph done negative NSCLC harboring a sensitizing EGFR mutation
1 trial -
D9106C00001
AstraZeneca AB
Patients with resectable Non-small Cell Lung Cancer (Stage IIA to IIIB; either squamous or non-squamous).
1 trial -
D910DC00001
AstraZeneca AB
Histologically or cytologically confirmed Locoregional Hepatocellular Carcinoma (HCC) and successfully completed curative therapy (resection or ablation)
1 trial
Frequently asked questions
What is the Clinical Development Intelligence Platform?
It is NovaPharmaNews pipeline intelligence hub covering 20,548 clinical development programs — not just a directory. It includes phase distribution dashboards, therapeutic area overviews, NDA/BLA watchlists, upcoming readouts, company pipeline rankings, competitive landscape maps, and personalized watchlists.
How does this compare to Evaluate Pharma or Citeline?
Like Evaluate Pharma and Citeline Trialtrove, we index ClinicalTrials.gov programs by sponsor, phase, and indication. Our platform adds cross-links to NovaPharmaNews company profiles, drug INN pages, patents, and congress readout calendars — improving crawl depth and reducing orphan program pages.
Where does pipeline data come from?
Program records derive from ClinicalTrials.gov and link to sponsor company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment decisions. See our data sources page for attribution.
Can I follow a company or program for updates?
Yes — use the watchlist forms on this page to follow sponsors, individual programs, disease clusters, or therapeutic areas. Alerts use the same subscription infrastructure as our events intelligence hub.